Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: A prospective cohort study

HIV Clinical Trials

Volumn 16, Issue 3, 2015, Pages 100-110

  Yeung, Man Wah ^a   Young, Jim ^b   Moodie, Erica ^a   Rollet Kurhajec, Kathleen C ^c   Schwartzman, Kevin ^a,d   Greenaway, Christina ^a,e   Cooper, Curtis ^f,g   Cox, Joseph ^a   Gill, John ^h   Hull, Mark ^i,j   Walmsley, Sharon ^k,l   Klein, Marina B ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^h Southern Alberta HIV Clinic   (Canada)

ⁱ BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^j ST PAUL S HOSPITAL   (Canada)

^k UNIVERSITY OF TORONTO   (Canada)

^l UNIVERSITY HEALTH NETWORK   (Canada)

more..

Author keywords

Health services; Hepatitis C virus treatment; HIV; Mortality; Quality of life; Sustained virologic response

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; SUBSTANCE USE; TREATMENT RESPONSE; CANADA; COMPLICATION; DRUG DEPENDENCE; DRUG EFFECTS; HEALTH SERVICE; HEPACIVIRUS; MIDDLE AGED; MORTALITY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; UTILIZATION;

ADULT; CANADA; COHORT STUDIES; COINFECTION; FEMALE; HEALTH SERVICES; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SUBSTANCE-RELATED DISORDERS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 84947557820     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.13039/501100000024     Document Type: Article

References (46)

1. Remis RS. Modelling the incidence and prevalence of hepatitis C infection and its sequelae in Canada. Ottawa: Public Health Agency of Canada; 2007.
2. Shepard CW, Finelli L, Alter M J. Global epidemiology of hepatitis C virus infection. LancetInfectDis. 2005;5(9):558-567.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
4. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632-1641.
5. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. JV Engl J Med. 2013;368(20):1867-1877.
6. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONE-STAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515-523.
7. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. JViral Hejm. 2012;19(7):449-464.
8. Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furhrer J, McCabe RE, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2003;36(3):363-367.
9. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garćia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. JV Engl J Med. 2004;351(5):438-450.
10. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with tela-previr for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159(2):86-96.
11. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis. 2013;13(7):597-605.
12. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52(7):889-900.
13. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A Sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8(3):280-288e281.
14. McHutchison JG, Ware JE Jr, Bayliss MS, Pianko S, Albrecht JK, Cort S, etal. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol. 2001;34(1):140-147.
15. Berenguer J, Alvarez-Pellicer J, Martin PM, Lopez-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatoloev. 2009;50(2):407-413.
16. Berenguer J, Rodŕiguez E, Miralles P, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis. 2012;55(5):728-736.
17. Myers RP, Liu M, Shaheen AA. The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol. 2008;22(4):381-387.
18. Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P, Peltekian K, etal. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol. 2014;28(5): 243-250.
19. Canadian Agency for Drugs and Technologies in Health (CADTH). Direct-acting antivirals for chronic hepatitis C genotype 1-project protocol. Volume 2, Issue 2A. CADTH Therapeutic Review Report; http://www.cadth.ca/media/pdf/TR0007-HepC-Protocol-e.pdf. Accessed July, 2014 2014
20. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepa-tology. 2012;55(1):49-57.
21. Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, et al. Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int J Epidemiol. 2010;39(5):1162-1169.
22. EuroQol-Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
23. Klein MB, Rollet KC, Saeed S, Cox J, Potter M, Cohen J, et al. HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality. HIV Med. 2013;14:10-20.
24. Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterolosv. 2013;144(7):1450-1455e1452.
25. Chevaliez S, Pawlotsky JM. Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int J Med Sci. 2006;3(2):35-40.
26. Monto A, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology. 2004;39(3):826-834.
27. Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, Fix O, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr. 2005;40(5):538-544.
28. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibro sis and cirrhosis in patients with chronic hepatitis C. Hepatolopv. 2003;38(2):518-526.
29. Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr. 2007; 44(4):463-469.
30. Bansback N, Tsuchiya A, Brazier J, Anis A. Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. PLoS One. 2012;7(2):e31115.
31. Wu AW, Hanson KA, Harding G, Haider S, Tawadrous M, Khachatryan A, et al. Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies. Health Qual Life Outcomes. 2013;11:42.
32. Wu AW, Jacobson KL, Frick KD, Clark R, Revicki DA, Freedberg KA, et al. Validity and responsiveness of the euroqol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Qual Life Res. 2002;11(3):273-282.
33. Unal G, de Boer JB, Borsboom GJ, Brouwer JT, Essink-Bot M, de Man RA. A psychometric comparison of health-related quality of life measures in chronic liver disease. J Clin Epidemiol. 2001;54(6):587-596.
34. Tran BX, Nguyen LT. Impact of methadone maintenance on health utility, health care utilization and expenditure in drug users with HIV/AIDS. Int JDrug Policy. 2013;24(6):e105-e110.
35. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.
36. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98(3):630-638.
37. Razavi H, Elkhoury AC, Elbasha E, Estes C, Pasini K, Poynard T, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Heggtology. 2013;57(6):2164-2170.
38. Werb D, Wood E, Kerr T, Hershfield N, Palmer RW, Remis RS. Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026. IntJDrugPolicy. 2011; 22(1):70-76.
39. Krajden M, Kuo M, Zagorski B, Alvarez M, Yu A, Krahn M. Health care costs associated with hepatitis C: a longitudinal cohort study. Can J Gastroenterol. 2010;24(12):717-726.
40. Grady BP, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis. 2013;57(Suppl 2):S105-S110.
41. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009;200(8):1216-1226.
42. Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat. 2007; 14(6):413-418.
43. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013; 368(20):1859-1861.
44. Langendam MW, van Haastrecht HJ, van Ameijden EJ. The validity of drug users' self-reports in a non-treatment setting: prevalence and predictors of incorrect reporting methadone treatment modalities. Int J Epidemiol. 1999;28(3):514-520.
45. Digiusto E, Seres V, Bibby A, Batey R. Concordance between urinalysis results and self-reported drug use by applicants for methadone maintenance in Australia. Addict Behav. 1996;21(3):319-329.
46. Weissman JS, Levin K, Chasan-Taber S, Massagli MP, Seage GR 3rd, Scampini L. The validity of self-reported healthcare utilization by AIDS patients. AIDS. 1996;10(7):775-783.